By Donna Loyle, communications specialist, LIMR
In this brand-new trial at Main Line Health, researchers seek to determine whether systematic monitoring of symptoms via patient-reported outcome (PRO) measures during routine outpatient cancer care improves meaningful clinical outcomes. Patients diagnosed with an advanced/metastatic form of any cancer (except leukemia or indolent lymphoma) and who are undergoing cancer treatment are eligible to participate.
Symptoms are common during cancer treatment, but they frequently go undetected by clinicians between visits. As such there is substantial and growing interest to integrate PROs into routine practice to improve detection and management of patients’ symptoms. Patient self-reporting of symptoms — with alerts to clinicians for severe symptoms — offers a potential approach to flag concerning symptoms and prevent complications. The study is designed to test whether patients’ outcomes and utilization of services can be improved through symptom monitoring via PROs between visits.
Participants complete questionnaires electronically, either in their homes or at Main Line Health. Questionnaires can also be completed on paper in the clinic, if needed. Patients complete the questionnaires upon enrollment, and then at the following months: 1, 3, 6, 9, and 12. The questionnaires are available in English, Spanish or Mandarin Chinese.
Whenever a concerning symptom is reported by a trial participant, an automated email alert notification will be sent to the clinical trial coordinator (and Nurse Champion, if applicable), who will forward the alert to the responsible clinical nurse (or other covering clinician). Within 72 hours, the coordinator will document what action(s), if any, were taken by the nurse in response to the alert.
Must be at least 21 years old and have been diagnosed with advanced or metastatic cancer of any type, except leukemia or indolent lymphoma
Must be undergoing outpatient cancer treatment with palliative/non-curative intent (e.g., chemotherapy, targeted therapy, immunotherapy)
Must not be undergoing curative intent (e.g., adjuvant chemotherapy for breast, lung, or ovarian cancer; primary curative therapy for testis cancer or lymphoma) or receiving hormonal therapy
Trial #AFT-39 is available at all Main Line Health acute care hospitals. Paul Gilman, MD, is the principal investigator. For more, visit https://www.mainlinehealth.org/research/clinical-trials/aft-39